The competitive combination of cDCBLD2 with miR-345-5p resulted in increased TOP2A protein levels, reduced cleavage of apoptotic marker proteins PARP and caspase-3, and a decreased drug killing effect of sorafenib by inhibiting apoptosis in HCC cells. This evidence concerns the gene PARP1 and hepatocellular carcinoma.